NCT05729646View on ClinicalTrials.gov

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2029

Conditions
Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionMismatch Repair Deficiency
Interventions
DRUG

Toripalimab

Perioperative Toripalimab, 240 mg IV infusion

DRUG

Oxaliplatin

Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

DRUG

S1

S-1 orally intake as perioperative chemotherapy

Trial Locations (8)

310003

RECRUITING

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

NOT_YET_RECRUITING

The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

313099

NOT_YET_RECRUITING

Huzhou Central Hospital, Huzhou

315010

NOT_YET_RECRUITING

Ningbo First Hospital, Ningbo

315048

NOT_YET_RECRUITING

Ningbo Medical Center LiHuiLi Hospital, Ningbo

315099

NOT_YET_RECRUITING

Ningbo Second Hospital, Ningbo

317099

NOT_YET_RECRUITING

Taizhou Hospital, Taizhou

323000

NOT_YET_RECRUITING

Lishui Central Hospital, Lishui

All Listed Sponsors
lead

Yu jiren

OTHER